SCHEMBL549432

SCHEMBL549432

C[N+](C)(C)CCOP(=O)([O-])Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
BCHE P06276 1/20 0.54
ACHE P22303 1/20 0.54
MAPK1 P28482 3/20 0.49
ALDH1A1 P00352 3/20 0.49
CYP3A4 P08684 2/20 0.49
HSD17B10 Q99714 2/20 0.49
TSHR P16473 1/20 0.49
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 1/20 0.49
THRB P10828 1/20 0.49
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
KCNH2 Q12809 5/20 0.42
ESR1 P03372 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CDC25A P30304 1/20 0.42
AGTR1 P30556 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4542384 0.85 CES2 (0.63) CA1CA2BCHEACHEMAPK1
SCHEMBL19244145 0.82 LMNA (0.46) MAPK1ALDH1A1CYP3A4TSHRLMNA
Phosphoric Acid SCHEMBL5392062 0.82 DRD2 (0.51) CA1CA2BCHEACHEALDH1A1
SCHEMBL2825992 0.81 LMNA (0.45) CA1CA2MAPK1ALDH1A1TSHR
SCHEMBL8154893 0.81 LMNA (0.47) CA1CA2LMNASMN1; SMN2KCNH2
Phosphoric Acid SCHEMBL5392068 0.80 CA1 (0.51) CA1CA2BCHEACHEALDH1A1
SCHEMBL15021236 0.79 MAPT (0.55) ALDH1A1KCNH2MAPTDRD2DRD4
SCHEMBL2912361 0.78 NPC1 (0.48) MAPK1ALDH1A1LMNASMN1; SMN2KCNH2
SCHEMBL19244142 0.78 PKM (0.43) CA1CA2BCHEACHEMAPK1
P-Nitrophenylphosphate SCHEMBL3992995 0.78 CA1 (0.53) CA1CA2BCHEACHEMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2953978-B1 PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF TPCERA LTD (IL) 2024-10-23 EP claimed
US-9075054-B2 C-reactive protein imprinted polymer film and microchip system utilizing the same MACKAY MEMORIAL HOSPITAL (TW) 2015-07-07 US claimed
US-20130156645-A1 C-REACTIVE PROTEIN IMPRINTED POLYMER FILM AND MICROCHIP SYSTEM UTILIZING THE SAME NATIONAL TSING HUA UNIVERSITY (TW) 2013-06-20 US claimed
EP-3725878-B1 PHOSPHOLIPASE C AND ENCODING GENE THEREOF WILMAR SHANGHAI BIOTECHNOLOGY RES & DEV CT CO LTD (CN) 2026-04-01 EP disclosed
US-20250346872-A1 MUTATED PHOSPHOLIPASE C ENZYME KECLON SA (AR) 2025-11-13 US disclosed
US-20250223510-A1 METHOD FOR DEGUMMING AND REFINING OF VEGETABLE OIL NOVOZYMES A/S (DK) 2025-07-10 US disclosed
CN-117187211-B Preparation method and application of phospholipase C crystals and phospholipase C mutants 华南理工大学 2025-04-01 CN disclosed
US-20240425840-A1 FUSION PROTEINS, RECOMBINANT BACTERIA, AND EXOSPORIUM FRAGMENTS FOR PLANT HEALTH SPOGEN BIOTECH INC (US) 2024-12-26 US disclosed
EP-4463531-A1 MUTATED PHOSPHOLIPASE C ENZYME Keclon SA (AR) 2024-11-20 EP disclosed
CN-118541466-A Mutant phospholipase C enzymes 凯科隆股份公司 2024-08-23 CN disclosed
US-12031164-B2 Fusion proteins, recombinant bacteria, and exosporium fragments for plant health SPOGEN BIOTECH INC. (US) 2024-07-09 US disclosed
WO-2002051853-A1 DETECTION OF MICROBIAL METABOLITES BIOSYNTH AG (CH) 2002-07-04 WO disclosed
EP-1219628-A1 Novel substrates for detection of microbial metabolites Biosynth AG (CH) 2002-07-03 EP disclosed
US-20020028215-A1 NOVEL VACCINES AND PHARMACEUTICAL COMPOSITIONS USING MEMBRANE VESICLES OF MICROORGANISMS, AND METHODS FOR PREPARING SAME KADURUGAMUWA JAGATH L (CA) 2002-03-07 US disclosed
EP-0841944-A2 NOVEL VACCINES AND PHARMACEUTICAL COMPOSITIONS USING MEMBRANE VESICLES OF MICROORGANISMS, AND METHODS FOR PREPARING SAME UNIVERSITY OF GUELPH (CA) 1998-05-20 EP disclosed
WO-1997005899-A2 NOVEL VACCINES AND PHARMACEUTICAL COMPOSITIONS USING MEMBRANE VESICLES OF MICROORGANISMS, AND METHODS FOR PREPARING SAME UNIVERSITY OF GUELPH (CA) 1997-02-20 WO disclosed
US-5272258-A Monoclonal antibodies to C-reactive protein RUSH-PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER (US) 1993-12-21 US disclosed
EP-0479922-A4 MONOCLONAL ANTIBODIES TO C-REACTIVE PROTEIN 1992-06-17 EP disclosed
EP-0479922-A1 MONOCLONAL ANTIBODIES TO C-REACTIVE PROTEIN RUSH-PRESBYTERIAN-ST.LUKE'S MEDICAL CENTER (US) 1992-04-15 EP disclosed
WO-1991000872-A1 MONOCLONAL ANTIBODIES TO C-REACTIVE PROTEIN RUSH-PRESBYTERIAN-ST. LUKE'S MEDICAL CENTRE (US) 1991-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12031164-B2 Fusion proteins, recombinant bacteria, and exosporium fragments for plant health ENGASE, LCT, CPB1 CA1 1287/4885CA2 641/4885BCHE 42/4885
US-20240425840-A1 FUSION PROTEINS, RECOMBINANT BACTERIA, AND EXOSPORIUM FRAGMENTS FOR PLANT HEALTH ENGASE, LCT, CPB1 CA1 1287/4885CA2 641/4885BCHE 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.